Waltham, MA-based Dynogen announced today that it will go public in a reverse merger with a subsidiary of California’s Apex Bioventures. The subsidiary, Apex Bioventures Acquisition (AMEX: [[ticker:PEX]]) was set up for the purpose of acquiring a private firm. The Boston Business Journal has a nice run-down of the details of the somewhat unusual deal, under which Dynogen shareholders will receive some $98 million in Apex Bioventures stock.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
